Home » Stocks » GW Pharmaceuticals

GW Pharmaceuticals PLC (GWPH)

Stock Price: $91.01 USD -3.99 (-4.20%)
Updated Oct 26, 2020 1:32 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 2.83B
Revenue (ttm) 441.98M
Net Income (ttm) -55.50M
Shares Out 31.14M
EPS (ttm) -1.78
PE Ratio n/a
Forward PE 103.09
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 26, 2020
Last Price $91.01
Previous Close $95.00
Change ($) -3.99
Change (%) -4.20%
Day's Open 94.57
Day's Range 90.85 - 95.49
Day's Volume 205,297
52-Week Range 67.98 - 141.98

More Stats

Market Cap 2.83B
Enterprise Value 2.38B
Earnings Date (est) Nov 3, 2020
Ex-Dividend Date n/a
Shares Outstanding 31.14M
Float 25.61M
EPS (basic) -0.02
EPS (diluted) -1.78
FCF / Share -3.39
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.96M
Short Ratio 12.25
Short % of Float 19.35%
Beta 1.74
PE Ratio n/a
Forward PE 103.09
P/FCF Ratio n/a
PS Ratio 6.41
PB Ratio 4.22
Revenue 441.98M
Operating Income -54.00M
Net Income -55.50M
Free Cash Flow -106.13M
Net Cash 452.83M
Net Cash / Share 14.54
Gross Margin 64.29%
Operating Margin -12.22%
Profit Margin -12.60%
FCF Margin -24.01%
ROA -3.94%
ROE -7.68%
ROIC -19.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (17)

Buy 15
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(109.19% upside)
Current: $91.01
Target: 190.38
*Average 12-month price target from 16 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth2344.31%47.61%-32.22%-
Gross Profit2846.754.118.91
Operating Income-118-289-166-129
Net Income-9.02-295-170-91.70
Shares Outstanding372334306272
Earnings Per Share--0.11-0.07-0.04
Operating Cash Flow-123-232-149-120
Capital Expenditures61.63-32.89-20.10-12.91
Free Cash Flow-61.84-265-169-133
Cash & Equivalents537355322-
Total Debt27.225.916.35-
Net Cash / Debt510349316-
Book Value726415381-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name GW Pharmaceuticals PLC
Country United Kingdom
Employees 901
CEO Justin D. Gover

Stock Information

Ticker Symbol GWPH
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NASDAQ: GWPH
IPO Date May 1, 2013


GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, Dravet syndrome, and Lennox-Gastaut syndrome, as well as in phase III clinical trials for the treatment of tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of for schizophrenia, autism spectrum disorder, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.